Published in Eur Heart J on May 02, 2013
Sick leave and a smoking ban. Eur Heart J (2013) 0.75
2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens (2007) 20.09
2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens (2013) 18.17
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet (2009) 13.64
2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2013) 12.73
Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet (2004) 11.13
2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2007) 9.43
Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA (2003) 9.06
Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension (2011) 5.73
Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension (2003) 5.63
The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens (2003) 4.91
Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens (2009) 4.87
2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens (2007) 4.59
European Society of Hypertension position paper on ambulatory blood pressure monitoring. J Hypertens (2013) 4.28
Working Group on Blood Pressure Monitoring of the European Society of Hypertension International Protocol for validation of blood pressure measuring devices in adults. Blood Press Monit (2002) 4.02
Prevalence and factors associated with circadian blood pressure patterns in hypertensive patients. Hypertension (2009) 3.93
Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA (2003) 3.71
European Society of Hypertension guidelines for blood pressure monitoring at home: a summary report of the Second International Consensus Conference on Home Blood Pressure Monitoring. J Hypertens (2008) 3.32
The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypertens (2005) 3.27
Management of high blood pressure in children and adolescents: recommendations of the European Society of Hypertension. J Hypertens (2009) 3.13
The effectiveness of disease management programmes in reducing hospital re-admission in older patients with heart failure: a systematic review and meta-analysis of published reports. Eur Heart J (2004) 2.85
Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet (2004) 2.78
Benefits and risks of more intensive blood pressure lowering in hypertensive patients of the HOT study with different risk profiles: does a J-shaped curve exist in smokers? J Hypertens (2003) 2.72
Metabolic syndrome in the Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) study: daily life blood pressure, cardiac damage, and prognosis. Hypertension (2006) 2.65
2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension. Blood Press (2013) 2.62
Genome-wide association study of blood pressure extremes identifies variant near UMOD associated with hypertension. PLoS Genet (2010) 2.24
Visit-to-visit blood pressure variability, carotid atherosclerosis, and cardiovascular events in the European Lacidipine Study on Atherosclerosis. Circulation (2012) 2.21
Influence of age, risk factors, and cardiovascular and renal disease on arterial stiffness: clinical applications. Am J Hypertens (2002) 2.15
Malignant hypertension in patients treated with vascular endothelial growth factor inhibitors. J Clin Hypertens (Greenwich) (2012) 2.03
The vasodilatory response of skin microcirculation to local heating is subject to desensitization. Microcirculation (2009) 2.02
Peroxynitrite is a major trigger of cardiomyocyte apoptosis in vitro and in vivo. Free Radic Biol Med (2006) 1.99
Systolic blood pressure, diastolic blood pressure, and pulse pressure: an evaluation of their joint effect on mortality. Ann Intern Med (2003) 1.98
Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Press (2009) 1.98
Night-time heart rate cut-off point definition by resting office tachycardia in untreated hypertensive patients: data of the Spanish ABPM registry. J Hypertens (2014) 1.97
Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial. J Hypertens (2004) 1.87
[PREVENCAT study: control of cardiovascular risk in primary care]. Med Clin (Barc) (2005) 1.76
Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial. J Am Coll Cardiol (2010) 1.74
Tolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives. Am J Hypertens (2002) 1.74
The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy. Hypertension (2006) 1.71
Clinical differences between resistant hypertensives and patients treated and controlled with three or less drugs. J Hypertens (2012) 1.71
Riskard 2005. New tools for prediction of cardiovascular disease risk derived from Italian population studies. Nutr Metab Cardiovasc Dis (2005) 1.65
Usual sleep duration and cognitive function in older adults in Spain. J Sleep Res (2009) 1.63
Reproducibility of the circadian blood pressure pattern in 24-h versus 48-h recordings: the Spanish Ambulatory Blood Pressure Monitoring Registry. J Hypertens (2007) 1.62
Ambulatory blood pressure monitoring in hypertensive patients with high cardiovascular risk: a cross-sectional analysis of a 20,000-patient database in Spain. J Hypertens (2007) 1.60
Prediction of cardiovascular outcome by estimated glomerular filtration rate and estimated creatinine clearance in the high-risk hypertension population of the VALUE trial. J Hypertens (2007) 1.59
European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring. J Hypertens (2014) 1.58
Health-related quality of life as a predictor of hospital readmission and death among patients with heart failure. Arch Intern Med (2005) 1.57
A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. J Hypertens (2011) 1.57
Studies on left ventricular hypertrophy regression in arterial hypertension: a clear message for the clinician? Am J Hypertens (2008) 1.55
Socioeconomic position in childhood and cardiovascular risk factors in older Spanish people. Int J Epidemiol (2004) 1.54
Abnormalities in ambulatory blood pressure monitoring in hypertensive patients with diabetes. Hypertens Res (2011) 1.52
Association of central and peripheral pulse pressure with intermediate cardiovascular phenotypes. J Hypertens (2012) 1.49
Differences between office and ambulatory blood pressures in children and adolescents attending a hospital hypertension clinic. J Hypertens (2013) 1.49
Angiotensin receptor blockers: therapeutic targets and cardiovascular protection. Blood Press (2005) 1.49
Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy. J Hypertens (2002) 1.49
Cardiovascular risk stratification according to the 2003 ESH-ESC guidelines in uncomplicated patients with essential hypertension: comparison with the 1999 WHO/ISH guidelines criteria. Blood Press (2004) 1.48
Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE). Am J Hypertens (2005) 1.47
Indexation criteria of ventricular mass and predictive role of blood pressure and body composition. Am J Hypertens (2005) 1.46
Microalbuminuria breakthrough under chronic renin-angiotensin-aldosterone system suppression. J Hypertens (2012) 1.45
[2005 Spanish guidelines in diagnosis and treatment of arterial hypertension]. Med Clin (Barc) (2005) 1.45
[Prevalence of depression and associated medical and psychosocial factors in elderly hospitalized patients with heart failure in Spain]. Rev Esp Cardiol (2006) 1.44
Relationships of different types of event to cardiovascular death in trials of antihypertensive treatment: an aid to definition of total cardiovascular disease risk in hypertension. J Hypertens (2014) 1.44
Assessment of long-term antihypertensive treatment by clinic and ambulatory blood pressure: data from the European Lacidipine Study on Atherosclerosis. J Hypertens (2007) 1.42
[Prevalence of target organ damage and metabolic abnormalities in resistant hypertension]. Med Clin (Barc) (2011) 1.42
Inhibition of the renin-angiotensin-aldosterone system: is there room for dual blockade in the cardiorenal continuum? J Hypertens (2012) 1.41
The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials. J Hypertens (2011) 1.41
Role of echocardiography and carotid ultrasonography in stratifying risk in patients with essential hypertension: the Assessment of Prognostic Risk Observational Survey. J Hypertens (2002) 1.41
Eligibility to treatment and economic effect of the implementation of the new U.S. or European Society of Hypertension/European Society of Cardiology hypertension guidelines. J Hypertens (2015) 1.40
Assessment of coronary vasoreactivity by multidetector computed tomography: feasibility study with rubidium-82 cardiac positron emission tomography. Circ J (2011) 1.40
Sepsis up-regulates the expression of connexin 40 in rat aortic endothelium. Crit Care Med (2005) 1.40
The management of the type 2 diabetic patient with hypertension - too late and too little: suggested improvements. Blood Press (2008) 1.40
[Cognitive assessment of elderly patients in the emergency department: a comparison between standard tools, medical records and physicians' perception]. Rev Esp Geriatr Gerontol (2010) 1.40
Pulse wave analysis of aortic pressure: diastole should also be considered. J Hypertens (2013) 1.39
[Impact of infection on mortality in burn patients. Multivariate study in 1,773 intensive care unit patients]. Enferm Infecc Microbiol Clin (2009) 1.38
An international comparative study of blood pressure in populations of European vs. African descent. BMC Med (2005) 1.38
Sleep duration, general and abdominal obesity, and weight change among the older adult population of Spain. Am J Clin Nutr (2008) 1.33
Cardiovascular outcomes in hypertensive patients: comparing single-agent therapy with combination therapy. J Hypertens (2012) 1.32
Monitoring one-year compliance to antihypertension medication in the Seychelles. Bull World Health Organ (2002) 1.30
Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial. J Hypertens (2008) 1.29
Definition of kidney dysfunction as a cardiovascular risk factor: use of urinary albumin excretion and estimated glomerular filtration rate. Arch Intern Med (2008) 1.28
Baseline Characteristics and Early Blood Pressure Control in the CONVINCE Trial. Hypertension (2001) 1.26
Hypertension and microvascular remodelling. Cardiovasc Res (2008) 1.26
Low muscular mass and overestimation of microalbuminuria by urinary albumin/creatinine ratio. Hypertension (2005) 1.25
Survey of physicians' practices in the control of cardiovascular risk factors: the EURIKA study. Eur J Prev Cardiol (2011) 1.25
Intake of fried foods is associated with obesity in the cohort of Spanish adults from the European Prospective Investigation into Cancer and Nutrition. Am J Clin Nutr (2007) 1.23
Social network as a predictor of hospital readmission and mortality among older patients with heart failure. J Card Fail (2006) 1.23
Is a systolic blood pressure target <140 mmHg indicated in all hypertensives? Subgroup analyses of findings from the randomized FEVER trial. Eur Heart J (2011) 1.23